본문 바로가기 주메뉴 바로가기

Company

History & Achievements

Company History & Achievements
2025
  • Expanded Patent Protection – ONX-1006 patents granted in South Korea and the United States
  • Strong Preclinical Results – ONX-1006 demonstrated 20% greater tumor reduction than Abraxane at the same weekly PTX dose and a wide safety margin with no side effects at established dose levels
  • Continuous Treatment – Preclinical results support weekly treatment for one year or longer
  • Advanced Toward Human Trials – Continued preparation for Phase I/IIa evaluation of ONX-1006 in Stage IV pancreatic cancer
  • Expanded Clinical Network – Advanced collaborations with cancer researchers and clinical teams supporting ONX-1006 development
2024
  • Expanded Leadership – Strengthened corporate, intellectual property, operations, and scientific leadership
  • Expanded Patent Protection – ONX-1006 patents granted in Japan and Europe
  • Advanced Clinical Development – Progressed preparations for ONX-1006 human clinical evaluation in Stage IV pancreatic cancer
  • Established Clinical Goals – Set development goals including a 70% one year survival rate
2023
  • Oct. 06, 2023 Completed ONX-1006 GLP Toxicology Program – More than 30 preclinical tests and about 4,000 pages of supporting data
  • Wide Safety Margin – Repeat dose GLP tests in rats and beagle dogs supported continuous ONX-1006 administration
  • Completed 13 Week GLP Test – Weekly IV administration for 13 consecutive weeks followed by a 4 week recovery period
2022
  • Oct. 12, 2022 Professor Si Young Song joined the Onselex Clinical Advisory Board
  • Oct. 06, 2022 Professor Ho Soon Choi joined the Onselex Clinical Advisory Board
  • July 04, 2022 PANC-1 PK Test – Confirmed higher PTX accumulation in tumor tissue than in plasma
  • Mar. 30, 2022 Beagle GLP Toxicology Test – ONX-1006 completed dosing at 25 mg/kg PTX equivalent without dose related adverse effects
  • Mar. 03, 2022 AsPC-1 Pancreatic Cancer Test – Demonstrated statistically significant antitumor efficacy
2021
  • Dec. 14, 2021 Rat GLP Toxicology Test – Demonstrated a wide safety margin at high ONX-1006 doses
  • Oct. 06, 2021 Completed development of ONX-2006 oral anticancer drug for gastric and colon cancer
  • Sep. 27, 2021 AsPC-1 Pancreatic Cancer Test – Demonstrated strong antitumor efficacy
  • Aug. 10, 2021 Initiated third ONX-1006 xenograft efficacy test with Dt&C
  • Mar. 30, 2021 Completed national phase entry of the PCT international patent application
2020
  • Aug. 31, 2020 Initiated ONX-1006 preclinical testing program
  • Aug. 27, 2020 Initiated ONX-1006 animal efficacy testing
  • Aug. 25, 2020 Raised KRW 2.58 billion in investment capital in South Korea
  • July 10, 2020 Completed kilogram scale production of GLP grade ONX-1006
  • Mar. 19, 2020 Established Onselex Inc. in South Korea
2018
  • Aug. 01, 2018 Established Onselex Pharmaceuticals Inc. in the United States